Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...

EVERYONE’S talking about fat jabs – the ‘miracle’ injections trimming inches off waistlines, and helping turn the tide on the ...

Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Once swallowed, the pill expands to form a rigid triangle, mimicking the presence of food and triggering the sensation of satiety. The device remains in the stomach for several hours before passing ...

The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some ...

Eli Lilly & Co.’s stock soared 14% Thursday ... stage trial of a GLP-1 treatment for Type 2 diabetes and obesity in pill form. The last time the stock rose as much was June 29, 2000, when ...

Eli Lilly’s chair and chief executive officer, in a statement. “As a convenient once-daily pill, orforglipron may provide a new option.” Weight loss pills are as effective as injections A ...

Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last month.

Lilly’s pill, orforglipron, is cheaper to make and can be taken without fasting. Patrik Jonsson, head of Lilly’s weight-loss division, says it has “millions of tablets” available, ahead of its ...